Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Revolutionizing care for rare genitourinary tumours

Nature Reviews Urology volume 18, pages 69–70 (2021)Cite this article

Subjects

Management of rare genitourinary malignancies often depends on individual physicians’ discretion, resulting in non-standardized care. Furthermore, patients experience worse clinical outcomes than patients with common malignancies. Collaborative efforts such as the Global Society of Rare Genitourinary Tumors (GSRGT) are therefore necessary.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Gatta, G. et al. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet — a population-based study. Lancet Oncol. 18, 1022–1039 (2017).

    Article  Google Scholar 

  2. Gatta, G. et al. Rare cancers are not so rare: the rare cancer burden in Europe. Eur. J. Cancer 47, 2493–2511 (2011).

    Article  Google Scholar 

  3. Moch, H., Humphrey, P. A., Ulbright, T. M. & Reuter, V. E. (eds) WHO Classification of Tumours of the Urinary System and Male Genital Organs 4th Edn (IARC, 2016).

  4. Forman, D. et al. (eds) Cancer incidence in five continents Vol. X (IARC, 2014).

  5. Necchi, A. et al. Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies. Eur. Urol. 77, 439–446 (2020).

    Article  CAS  Google Scholar 

  6. Pederzoli, F. et al. Targetable gene fusions and aberrations in genitourinary oncology. Nat. Rev. Urol. 17, 613–625 (2020).

    Article  CAS  Google Scholar 

  7. Ray-Coquard, I. et al. Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions. Ann. Oncol. 23, 2442–2449 (2012).

    Article  CAS  Google Scholar 

  8. Tang, V. et al. Should centralized histopathological review in penile cancer be the global standard? BJU Int. 114, 340–343 (2014).

    PubMed  Google Scholar 

  9. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02305654 (2019).

  10. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02465060 (2020).

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy

    Andrea Necchi

  2. Urological Research Institute (URI), Unit of Urology, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy

    Filippo Pederzoli & Marco Bandini

  3. Moffitt Cancer Center and Research Institute, Tampa, FL, USA

    Philippe E. Spiess

Authors
  1. Andrea Necchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Filippo Pederzoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marco Bandini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Philippe E. Spiess
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philippe E. Spiess.

Ethics declarations

Competing interests

P.E.S. serves as Vice-Chair and panel member of the NCCN bladder and penile cancer committee and President of the Global Society of Rare GU Tumors. A.N. serves as panel member of the European Association of Urology (EAU) penile cancer guidelines and Vice-President of the Global Society of Rare GU Tumors. A.N. has received consulting fees from Astellas/Seattle Genetics, AstraZeneca, Bayer, Clovis Oncology, Ferring, Immunomedics, Incyte, Janssen, Merck, Rainier Therapeutics and Roche; grant and/or research support from AstraZeneca, Ipsen and Merck; and travel expenses and/or honoraria from AstraZeneca, Janssen, Merck, and Roche. F.P. and M.B. declare no competing interests.

Additional information

Related links

EC 141/2000: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32000R0141

EC 847/2000: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32000R0847

European Commission on rare diseases: https://ec.europa.eu/health/non_communicable_diseases/rare_diseases_en

Genetic and Rare Diseases Information Center: https://rarediseases.info.nih.gov/diseases/pages/31/faqs-about-rare-diseases

Global Society of Rare Genitourinary Tumors: https://www.gsrgt.com/

Orphan Drug Act: https://www.fda.gov/industry/designating-orphan-product-drugs-and-biological-products/orphan-drug-act-relevant-excerpts

Surveillance of Rare Cancers in Europe: http://www.rarecare.eu/

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Necchi, A., Pederzoli, F., Bandini, M. et al. Revolutionizing care for rare genitourinary tumours. Nat Rev Urol 18, 69–70 (2021). https://doi.org/10.1038/s41585-020-00402-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-020-00402-8

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer